Drugs / ZSP0678
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04137055 | Nov 2019 → Dec 2020 | metabolic dysfunction-associated steatohepatitis | Guangdong Raynovent Biotech Co., Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZSP0678 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04137055 ↗ |
| Route | Oral | “ZSP0678 tablet administered orally under fasted condition” NCT04137055 ↗ |